KR20230045075A - 아브도랄리맙을 사용한 피하 항-C5aR 길항제 치료 용법 - Google Patents

아브도랄리맙을 사용한 피하 항-C5aR 길항제 치료 용법 Download PDF

Info

Publication number
KR20230045075A
KR20230045075A KR1020237007878A KR20237007878A KR20230045075A KR 20230045075 A KR20230045075 A KR 20230045075A KR 1020237007878 A KR1020237007878 A KR 1020237007878A KR 20237007878 A KR20237007878 A KR 20237007878A KR 20230045075 A KR20230045075 A KR 20230045075A
Authority
KR
South Korea
Prior art keywords
ser
abdoralimab
c5ar
leu
val
Prior art date
Application number
KR1020237007878A
Other languages
English (en)
Korean (ko)
Inventor
까린 파뛰렐
Original Assignee
이나뜨 파르마 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이나뜨 파르마 에스.에이. filed Critical 이나뜨 파르마 에스.에이.
Publication of KR20230045075A publication Critical patent/KR20230045075A/ko

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020237007878A 2020-08-12 2021-08-06 아브도랄리맙을 사용한 피하 항-C5aR 길항제 치료 용법 KR20230045075A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063064442P 2020-08-12 2020-08-12
US63/064,442 2020-08-12
PCT/EP2021/072027 WO2022033981A1 (fr) 2020-08-12 2021-08-06 Schéma de traitement anti-antagoniste c5ar en sous-cutané avec avdoralimab

Publications (1)

Publication Number Publication Date
KR20230045075A true KR20230045075A (ko) 2023-04-04

Family

ID=77627086

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237007878A KR20230045075A (ko) 2020-08-12 2021-08-06 아브도랄리맙을 사용한 피하 항-C5aR 길항제 치료 용법

Country Status (8)

Country Link
US (1) US20230340140A1 (fr)
EP (1) EP4196501A1 (fr)
JP (1) JP2023537417A (fr)
KR (1) KR20230045075A (fr)
CN (1) CN116615454A (fr)
AU (1) AU2021324314A1 (fr)
CA (1) CA3194881A1 (fr)
WO (1) WO2022033981A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4397306A1 (fr) * 2023-01-05 2024-07-10 Dompe' Farmaceutici S.P.A. Inhibiteurs de c5ar1 destinés à être utilisés dans le traitement de pemphigoïde de la muqueuse oculaire et/ou de pemphigoïde de la muqueuse buccale

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480974A (en) 1993-06-18 1996-01-02 The Scripps Research Institute Antibodies to human C5a receptor
NL1015601C2 (nl) 2000-07-04 2002-01-08 Skf Eng & Res Centre Bv Lagereenheid met ge´ntegreerde moer, en actuator met een dergelijke eenheid.
EP1476469B1 (fr) 2002-01-25 2015-11-18 Novo Nordisk A/S Anticorps monoclonaux agissant contre des boucles extracellulaires de c5ar
CA2789061A1 (fr) 2010-02-26 2011-09-01 Henrik Parshad Compositions stables contenant des anticorps
CA2800188A1 (fr) 2010-05-28 2011-12-01 Novo Nordisk A/S Compositions stables multi-doses comprenant un anticorps et un agent conservateur
PL2718322T3 (pl) 2011-06-06 2019-07-31 Novo Nordisk A/S Lecznicze przeciwciała
WO2014180961A1 (fr) 2013-05-08 2014-11-13 Novo Nordisk A/S Utilisation d'antagonistes de c5ar
ES2893769T3 (es) * 2017-04-03 2022-02-10 Inflarx Gmbh Tratamiento de enfermedades inflamatorias con inhibidores de la actividad de C5a

Also Published As

Publication number Publication date
CN116615454A (zh) 2023-08-18
WO2022033981A1 (fr) 2022-02-17
JP2023537417A (ja) 2023-08-31
CA3194881A1 (fr) 2022-02-17
AU2021324314A9 (en) 2023-07-13
AU2021324314A1 (en) 2023-05-25
US20230340140A1 (en) 2023-10-26
EP4196501A1 (fr) 2023-06-21

Similar Documents

Publication Publication Date Title
US10882916B2 (en) Anti-C5a receptor antibodies
TW201839014A (zh) 抗-ilt4抗體及抗原結合片段
KR20230048439A (ko) 항-par-2 항체 및 이의 사용 방법
CN108178798B (zh) pH工程化的NGF抗体及其医药用途
JP2020535167A (ja) 抗pacap抗体
KR20230045075A (ko) 아브도랄리맙을 사용한 피하 항-C5aR 길항제 치료 용법
JP2021514960A (ja) 抗TrkA抗体
KR20230004659A (ko) 항-인간 신경 성장 인자 항체
CN110606892B (zh) 一种高亲和力高生物活性的lag-3抗体及其应用
CN111234021B (zh) 一种抗ccr5抗体及其在治疗肿瘤中的应用
JP2024074278A (ja) Lag-3およびpd-1/lag-3抗体
CA3239307A1 (fr) Anticorps caninises contre recepteur alpha 1 de l'interleukine-31 canine
WO2023094698A1 (fr) Anticorps anti-sirpg antagonistes spécifiques
MX2013013911A (es) Anticuerpos terapeuticos.

Legal Events

Date Code Title Description
A201 Request for examination